Summit Therapeutics Quarterly Cash Flow Statement
NASDAQ: SMMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
17.59+0.42 (+2.45%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 17.62 +0.17%
Summit Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Summit Therapeutics generated -$141.1 million of operating cash flow and spent $909,000 on capital expenditures. That left free cash flow of -$142.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Summit Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -215.70M | -189.42M | -219.17M | -231.79M | -565.71M | -62.91M | -61.20M | -56.25M | -60.38M | -43.47M | -36.57M | -21.27M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 46.00K | 44.00K | 42.00K | 42.00K | 37.00K | 25.00K | 22.00K | 20.00K | 20.00K | 27.00K | 30.00K | 32.00K |
| Stock-Based Compensation | 68.71M | 72.79M | 111.78M | 130.76M | 478.78M | 11.10M | 11.02M | 19.37M | 11.09M | 9.51M | 8.75M | 705.00K |
| Change in Working Capital | 4.80M | 8.01M | 4.60M | 3.85M | 20.84M | 3.82M | 4.17M | 5.56M | 2.62M | 4.01M | 4.64M | -322.00K |
| Operating Cash Flow | -141.12M | -122.29M | -101.94M | -93.08M | -66.74M | -61.17M | -48.67M | -30.30M | -33.00M | -30.13M | -19.46M | -14.90M |
| Capital Expenditures | -909.00K | -245.00K | -164.00K | -71.00K | 0 | -422.00K | -14.00K | -58.00K | -63.00K | -4.00K | -2.00K | -53.00K |
| Investing Cash Flow | 222.90M | -238.00K | -485.16M | -71.00K | 150.81M | 160.11M | 83.48M | -108.61M | -200.08M | 19.87M | 60.57M | -3.49M |
| Financing Cash Flow | 231.08M | 3.80M | 573.82M | 33.81M | 2.22M | 7.68M | -23.61M | 204.14M | 200.21M | 485.00K | 6.25M | 229.00K |
| Net Change in Cash | 312.85M | -118.75M | -13.29M | -59.32M | 86.35M | 106.66M | 11.09M | 65.34M | -32.86M | -9.81M | 47.63M | -18.32M |
| Free Cash Flow | -142.03M | -122.54M | -102.10M | -93.15M | -66.74M | -61.59M | -48.69M | -30.36M | -33.06M | -30.14M | -19.46M | -14.95M |
This table shows 12 quarterly periods of Summit Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SMMT's reporting calendar. What is a cash flow statement?